Andrographis Paniculata
9 benefits mapped to clinical evidence across supplements.
Dose per serving from products
28 products in our catalogue print how much Andrographis Paniculata a serving holds.
Most common: 25 mg to 50 mg, 36% of 28 products.
| Dose per serving | Products |
|---|---|
| 10 mg or less | 1 |
| 10 mg to 25 mg | 2 |
| 25 mg to 50 mg | 10 |
| 50 mg to 100 mg | 9 |
| 100 mg to 250 mg | 0 |
| 250 mg to 500 mg | 4 |
| 500 mg to 1 g | 1 |
| over 1 g | 1 |
Dose per serving from research
12 study groups in 8 studies say how much Andrographis Paniculata participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 1 g to 2.5 g, 33% of 12 study groups.
| Daily dose | Study groups |
|---|---|
| 100 mg to 250 mg | 2 |
| 250 mg to 500 mg | 3 |
| 500 mg to 1 g | 1 |
| 1 g to 2.5 g | 4 |
| 2.5 g to 5 g | 1 |
| over 5 g | 1 |
Benefit Evidence
Throat/nasal relief +53%
Overall symptoms improved 2.1x
Earache/runny nose reduced
Throat/nasal relief +53%
Overall symptoms improved 2.1x
Earache/runny nose reduced
Research sources
Respiratory comfort (7)
- Double-blind, placebo-controlled pilot and phase III study of activity of standardized Andrographis paniculata Herba Nees extract fixed combination (Kan jang) in the treatment of uncomplicated upper-respiratory tract infection
PubMed ID: 11081985
Standardized AP combination improved overall URTI and throat‑related symptoms in RCTs (respiratory symptom relief).
- A double blind, placebo-controlled study of Andrographis paniculata fixed combination Kan Jang in the treatment of acute upper respiratory tract infections including sinusitis
PubMed ID: 12487322
Kan Jang RCT reduced total URTI symptoms including nasal and throat complaints (respiratory comfort evidence).
- Comparative controlled study of Andrographis paniculata fixed combination, Kan Jang and an Echinacea preparation as adjuvant, in the treatment of uncomplicated respiratory disease in children
PubMed ID: 14750201
Pediatric trial found Kan Jang reduced nasal secretion and congestion and sped recovery vs comparators (respiratory benefit in children).
- Efficacy of Andrographis paniculata spray in acute pharyngitis: A randomized controlled trial
PubMed ID: 37821383
Topical A. paniculata throat spray produced faster symptomatic relief in acute viral sore throat vs chamomile (local respiratory/pharyngeal comfort).
- A randomized double blind placebo controlled clinical evaluation of extract of Andrographis paniculata (KalmCold) in patients with uncomplicated upper respiratory tract infection
PubMed ID: 20092985
KalmCold showed substantially greater overall efficacy for uncomplicated URTI vs placebo (improved respiratory symptoms).
- Efficacy and safety of AP-Bio®(KalmCold®) in participants with uncomplicated upper respiratory tract viral infection (common cold) - A phase III, double-blind, parallel group, randomized placebo-controlled trial
PubMed ID: 36842634
Phase III trial showed early reduction in common cold symptom scores and favorable nasal inflammation trends.
- Use of visual analogue scale measurements (VAS) to asses the effectiveness of standardized Andrographis paniculata extract SHA-10 in reducing the symptoms of common cold. A randomized double blind-placebo study
PubMed ID: 10589439
Standardized extract RCT reduced cold symptoms including nasal secretion and sore throat beginning by day 2–4 (respiratory comfort evidence).
Cold/flu relief (6)
- Comparative controlled study of Andrographis paniculata fixed combination, Kan Jang and an Echinacea preparation as adjuvant, in the treatment of uncomplicated respiratory disease in children
PubMed ID: 14750201
In children, Kan Jang reduced nasal secretion/congestion and accelerated recovery vs echinacea/standard care.
- Efficacy and safety of AP-Bio®(KalmCold®) in participants with uncomplicated upper respiratory tract viral infection (common cold) - A phase III, double-blind, parallel group, randomized placebo-controlled trial
PubMed ID: 36842634
Phase III RCT (300 participants) showed statistically significant Day‑3 reduction in WURSS‑21 global cold symptom score vs placebo.
- Use of visual analogue scale measurements (VAS) to asses the effectiveness of standardized Andrographis paniculata extract SHA-10 in reducing the symptoms of common cold. A randomized double blind-placebo study
PubMed ID: 10589439
Randomized placebo‑controlled trial showed significant, early reductions in cold symptoms (sore throat, runny nose) beginning by day 2–4.
- Double-blind, placebo-controlled pilot and phase III study of activity of standardized Andrographis paniculata Herba Nees extract fixed combination (Kan jang) in the treatment of uncomplicated upper-respiratory tract infection
PubMed ID: 11081985
Standardized AP combination improved URTI symptom scores in double‑blind RCTs (notably throat symptoms).
- A double blind, placebo-controlled study of Andrographis paniculata fixed combination Kan Jang in the treatment of acute upper respiratory tract infections including sinusitis
PubMed ID: 12487322
Kan Jang RCT significantly improved total URTI symptom scores vs placebo.
- A randomized double blind placebo controlled clinical evaluation of extract of Andrographis paniculata (KalmCold) in patients with uncomplicated upper respiratory tract infection
PubMed ID: 20092985
Large RCT (KalmCold) demonstrated ~52.7% higher overall efficacy versus placebo for uncomplicated URTI symptoms.
Cough & throat (6)
- Double-blind, placebo-controlled pilot and phase III study of activity of standardized Andrographis paniculata Herba Nees extract fixed combination (Kan jang) in the treatment of uncomplicated upper-respiratory tract infection
PubMed ID: 11081985
Phase III trial showed throat symptoms had the largest improvement with AP combination.
- Use of visual analogue scale measurements (VAS) to asses the effectiveness of standardized Andrographis paniculata extract SHA-10 in reducing the symptoms of common cold. A randomized double blind-placebo study
PubMed ID: 10589439
Strong RCT evidence with large OR favoring AP for sore throat reduction by day 4.
- A double blind, placebo-controlled study of Andrographis paniculata fixed combination Kan Jang in the treatment of acute upper respiratory tract infections including sinusitis
PubMed ID: 12487322
Kan Jang improved nasal/throat complaints in URTI trial.
- A randomized double blind placebo controlled clinical evaluation of extract of Andrographis paniculata (KalmCold) in patients with uncomplicated upper respiratory tract infection
PubMed ID: 20092985
KalmCold reduced sore throat among other URTI symptoms in a large RCT.
- Efficacy of Andrographis paniculata spray in acute pharyngitis: A randomized controlled trial
PubMed ID: 37821383
Topical A. paniculata throat spray RCT relieved acute viral sore throat faster than chamomile spray (~0.6 day faster).
- Efficacy and safety of AP-Bio®(KalmCold®) in participants with uncomplicated upper respiratory tract viral infection (common cold) - A phase III, double-blind, parallel group, randomized placebo-controlled trial
PubMed ID: 36842634
Phase III trial showed early reduction in cold symptoms including throat complaints by Day‑3 (supporting sore throat comfort).
Wellbeing (5)
- A double blind, placebo-controlled study of Andrographis paniculata fixed combination Kan Jang in the treatment of acute upper respiratory tract infections including sinusitis
PubMed ID: 12487322
Kan Jang RCT showed benefit in acute URTI including nasal/throat symptoms (seasonal relevance).
- Efficacy and safety of AP-Bio®(KalmCold®) in participants with uncomplicated upper respiratory tract viral infection (common cold) - A phase III, double-blind, parallel group, randomized placebo-controlled trial
PubMed ID: 36842634
Phase III trial demonstrated early symptomatic benefit in common cold (supports seasonal use).
- Use of visual analogue scale measurements (VAS) to asses the effectiveness of standardized Andrographis paniculata extract SHA-10 in reducing the symptoms of common cold. A randomized double blind-placebo study
PubMed ID: 10589439
RCT evidence of early cold symptom reduction supports use for seasonal cold symptom relief/prevention of symptom worsening.
- Double-blind, placebo-controlled pilot and phase III study of activity of standardized Andrographis paniculata Herba Nees extract fixed combination (Kan jang) in the treatment of uncomplicated upper-respiratory tract infection
PubMed ID: 11081985
AP combinations improved URTI symptoms across RCTs, relevant to seasonal respiratory wellness.
- A randomized double blind placebo controlled clinical evaluation of extract of Andrographis paniculata (KalmCold) in patients with uncomplicated upper respiratory tract infection
PubMed ID: 20092985
KalmCold large RCT showing meaningful URTI symptom reduction supports seasonal wellness use.
Illness recovery (4)
- A double blind, placebo-controlled study of Andrographis paniculata fixed combination Kan Jang in the treatment of acute upper respiratory tract infections including sinusitis
PubMed ID: 12487322
Kan Jang reduced total URTI symptom burden and may speed symptomatic recovery (trial evidence).
- Efficacy and safety of AP-Bio®(KalmCold®) in participants with uncomplicated upper respiratory tract viral infection (common cold) - A phase III, double-blind, parallel group, randomized placebo-controlled trial
PubMed ID: 36842634
Early reduction in cold symptoms at Day‑3 suggests faster symptomatic recovery in some patients.
- Andrographis paniculata extract (HMPL-004) for active ulcerative colitis
PubMed ID: 23044768
Multicenter UC RCT showed increased clinical response (especially at higher dose) consistent with supporting recovery from active colitis.
- Comparative controlled study of Andrographis paniculata fixed combination, Kan Jang and an Echinacea preparation as adjuvant, in the treatment of uncomplicated respiratory disease in children
PubMed ID: 14750201
Pediatric trial found Kan Jang accelerated recovery time from URTI vs comparators.
Inflammation (4)
- Andrographis paniculata extract (HMPL-004) for active ulcerative colitis
PubMed ID: 23044768
Dose‑dependent clinical response in UC indicates anti‑inflammatory effects in the gut.
- A double-blind, randomized, placebo-controlled study to assess the efficacy of Andrographis paniculata standardized extract (ParActin®) on pain reduction in subjects with knee osteoarthritis
PubMed ID: 30968986
ParActin® RCT in knee osteoarthritis produced significant reductions in pain, stiffness and improved function (anti‑inflammatory/analgesic effect).
- Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial
PubMed ID: 19408036
Randomized trial in rheumatoid arthritis showed improvements in swollen/tender joint counts and HAQ (clinical anti‑inflammatory effects).
- Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine
PubMed ID: 21114791
HMPL‑004 showed mucosal healing and remission similar to mesalazine, supporting anti‑inflammatory action in IBD.
Immune support (3)
- Double-blind, placebo-controlled pilot and phase III study of activity of standardized Andrographis paniculata Herba Nees extract fixed combination (Kan jang) in the treatment of uncomplicated upper-respiratory tract infection
PubMed ID: 11081985
Two RCTs of standardized extract improved URTI symptom and diagnosis scores, implying clinically relevant immune-related benefit.
- A randomized double blind placebo controlled clinical evaluation of extract of Andrographis paniculata (KalmCold) in patients with uncomplicated upper respiratory tract infection
PubMed ID: 20092985
Large RCT (KalmCold) showed ~52.7% greater overall efficacy vs placebo for uncomplicated URTI, consistent with immune-supportive symptomatic effects.
- Use of visual analogue scale measurements (VAS) to asses the effectiveness of standardized Andrographis paniculata extract SHA-10 in reducing the symptoms of common cold. A randomized double blind-placebo study
PubMed ID: 10589439
Randomized RCT showing faster reduction of common cold symptoms (clinical immune‑related benefit though no direct immune markers measured).
Digestive support (2)
- Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine
PubMed ID: 21114791
HMPL‑004 produced clinical remission/response and mucosal healing rates similar to mesalazine in UC (digestive/colonic benefit).
- Andrographis paniculata extract (HMPL-004) for active ulcerative colitis
PubMed ID: 23044768
Large multicenter RCT in mild–moderate ulcerative colitis showed dose‑dependent increase in clinical response, supporting GI therapeutic effect.
Metabolism (2)
- Phytochemical screening and preliminary clinical trials of the aqueous extract mixture of Andrographis paniculata (Burm. f.) Wall. ex Nees and Syzygium polyanthum (Wight.) Walp leaves in metformin treated patients with type 2 diabetes
PubMed ID: 30668423
As add‑on to metformin, an AP‑containing extract mixture improved fasting and postprandial glucose and reduced BMI over 8 weeks (mixture, small study).
- Effect of Andrographis paniculata Extract on Triglyceride Levels of the Patients with Hypertriglyceridemia: A Randomized Controlled Trial
PubMed ID: 26434249
RCT in hypertriglyceridemic patients: higher‑dose A. paniculata extract significantly reduced triglycerides similar to gemfibrozil over 8 weeks.
Similar by evidence
Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.
Products with Andrographis Paniculata
Search all60 products whose verified label declares Andrographis Paniculata — not every bottle that mentions it in a title.